18 Jan 2022

Positive Top-Line Results for BIMZELX[®]▼(bimekizumab) in Phase 3 Non-Radiographic Axial Spondyloarthritis Study

Read More
8 Jan 2022

Disposals of own shares

Read More
3 Jan 2022

Disposals of own shares

Read More
21 Dec 2021

Disposals of own shares

Read More
16 Dec 2021

Positive Top-Line Results for BIMZELX[®]▼(bimekizumab) in Phase 3 Ankylosing Spondylitis Trial

Read More
10 Dec 2021

UCB announces positive Phase 3 results for rozanolixizumab in generalized myasthenia gravis

Read More
3 Dec 2021

Disposals of own shares

Read More
3 Dec 2021

UCB to present new data at the American Epilepsy Society 75th Annual Meeting 2021 reinforcing long-standing commitment to advancing epilepsy treatment and care

Read More
2 Dec 2021

UCB Announces Global Partnership to Bring Disease-Modifying Therapies to People Living with Parkinson’s Disease

Read More
30 Nov 2021

UCB and Chiesi enter global license agreement for zampilimab a novel monoclonal antibody for fibrotic lung diseases

Read More
Subscribe to